Aug 2026· JACC: Cardiovascular Interventions· Vol 19 16, pp.
2204-2216
· 1 citation· 10 references
Medicine
TL;DR
In a national registry, redo-TAVR with the Evolut platform was associated with low procedural complication rates and clinical outcomes comparable with those observed with native TAVR and support redo-TAVR with Evolut as a feasible and effective treatment strategy in appropriately selected patients.
Abstract
Background
Redo-transcatheter aortic valve replacement (TAVR) for failed transcatheter heart valves is expected to increase, but data on outcomes with self-expanding valves remain limited.
Objectives
The aims of this study were to evaluate procedural, clinical, and quality-of-life outcomes following redo-TAVR using self-expanding Evolut valves and to compare these outcomes with those among a contemporary native TAVR cohort.
Methods
Outcomes after redo-TAVR with Evolut R, Evolut PRO, and Evolut PRO+ valves in the Society of Thoracic Surgeons/American College of Cardiology TVT (Transcatheter Valve Therapy) Registry were analyzed and compared with outcomes after native-valve TAVR using the same valve platform during the same study period. The primary endpoints were all-cause mortality, stroke, and readmission at 30 days and 1 year.
Results
Among 439 redo-TAVR patients (mean age 78.9 ± 9.8 years, 63.1% women), procedural complication rates were low. Redo-TAVR reduced transvalvular gradients at 1 year, although gradients remained modestly higher than after native TAVR (11.3 ± 6.1 mm Hg vs 8.2 ± 4.6 mm Hg; P < 0.001). After adjustment, clinical outcomes were similar between redo-TAVR and native TAVR at 30 days (mortality adjusted HR: 0.66 [95% CI: 0.39-1.13; P = 0.129]; stroke adjusted HR: 0.95 [95% CI: 0.54-1.68; P = 0.853]; readmission adjusted HR: 0.88 [95% CI: 0.65-1.20; P = 0.422]) and 1-year (mortality adjusted HR: 0.91 [95% CI: 0.72-1.15; P = 0.441]; stroke adjusted HR: 0.91 [95% CI: 0.63-1.34; P = 0.644]; readmission adjusted HR: 0.92 [95% CI: 0.76-1.13; P = 0.439]). Improvements in functional status and quality of life were observed early after redo-TAVR and were sustained through 1 year. Findings were consistent across prespecified subgroups.
Conclusions
In a national registry, redo-TAVR with the Evolut platform was associated with low procedural complication rates and clinical outcomes comparable with those observed with native TAVR. These findings support redo-TAVR with Evolut as a feasible and effective treatment strategy in appropriately selected patients.
BACKGROUND
As transcatheter aortic valve implantation (TAVI) expands to younger and lower-risk populations, failed transcatheter heart valves are increasingly encountered, yet the optimal reintervention strategy remains uncertain. This meta-analysis aimed to compare the outcomes of redo-TAVI (TAVI-in-TAVI) versus surgi...
N. Ktenopoulos, A. Apostolos, D. Terentes-Printzios et al.· Journal of the American Hear...· 1 citation
BACKGROUND
Most evidence for transcatheter aortic valve replacement (TAVR) for valve-in-valve procedures comes from balloon-expandable and supra-annular self-expanding valves. However, data on intra-annular self-expanding valves remain limited. The objectives of this registry were to evaluate the short- and midterm out...
Jorge F. Chavez, G. Tirado-Conte, Y. Kobari et al.· Journal of the American Hear...· 0 citations
BACKGROUND
Self-expanding valves appear to have superior hemodynamics compared with balloon-expandable valves for valve-in-valve transcatheter aortic valve replacement (ViV-TAVR).
OBJECTIVES
This study aimed to compare echocardiographic and clinical outcome data between supra-annular self-expanding valves (SASEVs) an...
Kuljit Singh, E. Dababneh, M. Matta et al.· JACC: Cardiovascular Interve...· 1 citation
Among patients treated with newer-generation transcatheter valves, SEV demonstrated more favorable hemodynamic performance compared with BEV, however, short- and mid-term mortality rates remained similar between the two groups.
M. Baudo, S. Sicouri, Dimitrios E. Magouliotis et al.· Journal of Cardiovascular Me...· 1 citation
INTRODUCTION
The prevalence of bioprosthetic aortic valve failure is increasing due to the broader use of bioprosthetic valves, both surgical and transcatheter, and an ageing population. Registry data indicate a higher risk of coronary obstruction and elevated gradients following valve-in-valve transcatheter aortic val...
Hilal Khan, Mohamed Ali, Abdalazeem Ibrahem et al.· Catheterization and cardiova...· 0 citations
In patients at high or extreme surgical risk, TAVR with the self-expanding intra-annular transcatheter heart valve had similar 5-year overall survival, stroke rates, and valve function compared with commercially available valves.
Raj R. Makkar, Wen Cheng, Ron Waksman et al.· JACC: Cardiovascular Interve...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.